TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

02 июн 2021 07:00:01 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

27 май 2021 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis

25 май 2021 15:01:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports First Quarter 2021 Financial Results

06 май 2021 15:01:02 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

27 апр 2021 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Report First Quarter 2021 Financial Results

26 апр 2021 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

01 мар 2021 15:01:01 Источник Nasdaq GlobeNewswire

Travere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease

25 фев 2021 07:00:02 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

22 фев 2021 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA Nephropathy

18 фев 2021 15:30:00 Источник Nasdaq GlobeNewswire